Abstract:The 1-(2-nitrophenyl)thiosemicarbazide (TSC) derivative, (S)-1-[4-(4-benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl]amide (bradyzide; (S)-4), was recently disclosed as a novel, potent, orally active nonpeptide bradykinin (BK) B2 receptor antagonist. The compound inhibited the specific binding of [3H]BK to NG108-15 cell membrane preparations (rodent neuroblastoma-glioma) expressing B2 receptors with a K(i) of 0.5 +/- 0.2 nM. Compound (S)-4 also demonstrated oral efficacy against Freund's complete adjuvant (FCA)-induced mechanical hyperalgesia in rats with an ED50 value of 0.84 micromol/kg. After we optimized the terminal binding determinants projecting from the TSC framework, we found that it was possible to replace the potentially toxicophoric nitro and divalent sulfur moieties with only a 15-fold loss in binding affinity ((S)-14a). However, bradyzide and its congeners were found to have much lower affinities for cloned human B2 receptors, expressed in Cos-7 cells. The hitherto synthesized TSC series was screened against the human B2 receptor, and the dibenzosuberane (DBS) pharmacophore emerged as the key structural requirement for potency. Incorporation of this group resulted in a series of derivatives ((S)-14d,e and 19b-d) with K(i) ranges of 10.7-176 nM in NG108-15 cells (expressing the rodent B2 receptor) and 0.79-253 nM in Cos-7 cells (expressing the human B2 receptor). There was no evidence of agonist activity with any of the nonpeptides in any of the cell lines tested. In vivo, oral administration of compound 19c reversed FCA-induced and turpentine-induced mechanical hyperalgesia in rodents with ED50 values of 0.027 and 0.32 micromol/kg, respectively. The selectivity profiles of compounds (S)-14f and (S)-14g were also assessed to determine the conformational and/or steric preferences of the double-ring arrangement. The affinity of (S)-14 g for the human B2 receptor suggested that it may be a hydrophobic interaction with the ethane bridge of the DBS moiety that accounts for the increased potency of compounds (S)-14d,e and 19b,c at this receptor, by favoring a binding mode inaccessible to the unsubstituted diphenylmethyl derivative, (S)-4.

Function and structure of bradykinin receptor 2 for drug discovery

Cryo-EM Structures of Human Bradykinin Receptor-Gq Proteins Complexes

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein

Control of conformational equilibria in the human B2 bradykinin receptor. Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure

Structural insights into ligand recognition, activation, and signaling of the α 2A adrenergic receptor

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells

Conformation Analysis of a Bradykinin B2 Receptor Antagonist,a Proline Rich Undecapeptide

A2B adenosine receptor signaling and regulation

Prolyl Hydroxylase 2: A Novel Regulator Of Ss 2-Adrenoceptor Internalization

Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor

Structural basis of antagonist selectivity in endothelin receptors

Structural basis for ligand recognition of the human thromboxane A 2 receptor

Bradykinin Receptors in Ischemic Injury.

Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists

Binding characteristics of [3H]-JSM10292: a new cell membrane-permeant non-peptide bradykinin B2 receptor antagonist

Structural insights into ligand recognition and selectivity of the human hydroxycarboxylic acid receptor HCAR2

A Comparative NMR and Molecular Dynamics Study of the Conformations of Bradykinin B1 and B2, B2, and B1-specific Receptor Antagonists B-9430, B-9436, and B-9858.